Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

In relapsed/refractory acute myeloid leukemia (AML), the prognostic impact of complete remission (CR) and measurable residual disease (MRD) negativity is not well established. We retrospectively analyzed 141 patients with relapsed/refractory AML who received first salvage therapy and had MRD assesse...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Short, Nicholas J., Rafei, Hind, Daver, Naval, Hwang, Hyunsoo, Ning, Jing, Jorgensen, Jeffrey L., Kadia, Tapan M., DiNardo, Courtney D., Wang, Sa A., Jabbour, Elias, Popat, Uday, Oran, Betul, Cortes, Jorge, Konopleva, Marina, Yilmaz, Musa, Issa, Ghayas C., Kantarjian, Hagop, Ravandi, Farhad
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757010/
https://ncbi.nlm.nih.gov/pubmed/33351107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002811
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars